EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, indicating a -0.84% shift from the previous trading day.

Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...

There are exceptions, though. In a market that's broadly speaking priced for perfection, three Motley Fool contributors have identified what they think are bargain stocks to buy: Axsome Therapeutics ...

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).

What exactly drives a company's stock price higher? Intuitively, it's investor demand, but dig deeper — why are investors flocking to buy certain stocks beyond just fear of missing out?

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $48.05, representing a +0.47% change from its previous close.

Editor's note: This report contains potentially disturbing and offensive language. New Mexico State football offensive coordinator and quarterbacks coach Tyler Wright's social media contains more ...

Let's examine what this company is planning for the future, and figure out whether that makes its stock worth buying or not.

Seven out of 67 children who were given bluebird's (BLUE) gene therapy Skysona during clinical trials ended up developing ...

Longer Term Trading Plans for CRSP. Buy CRSP near 40.82 target 52.08 stop loss @ 40.7 Details; The technical summary data ...